MX345739B - Nuevo adyuvante. - Google Patents

Nuevo adyuvante.

Info

Publication number
MX345739B
MX345739B MX2013005222A MX2013005222A MX345739B MX 345739 B MX345739 B MX 345739B MX 2013005222 A MX2013005222 A MX 2013005222A MX 2013005222 A MX2013005222 A MX 2013005222A MX 345739 B MX345739 B MX 345739B
Authority
MX
Mexico
Prior art keywords
new adjuvant
adjuvant
new
antigen
combination
Prior art date
Application number
MX2013005222A
Other languages
English (en)
Other versions
MX2013005222A (es
Inventor
Alonso - Bedate Carlos
Soto - Alvarez Manuel
Parody - De La Fuente Nuria
Pico De Coaña - Suárez Yago
Original Assignee
Laboratorios Leti S L *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Leti S L * filed Critical Laboratorios Leti S L *
Publication of MX2013005222A publication Critical patent/MX2013005222A/es
Publication of MX345739B publication Critical patent/MX345739B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/008—Leishmania antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)

Abstract

La presente invención se refiere a una molécula de ácido nucleico para su uso como adyuvante cuando esta se encuentra operativamente unida a una secuencia de nucleótidos que codifica para un antígeno, por lo que la proteína que es codificada por dicha molécula de ácido nucleico puede usarse como adyuvante.
MX2013005222A 2010-11-10 2011-11-10 Nuevo adyuvante. MX345739B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41203410P 2010-11-10 2010-11-10
EP10190705 2010-11-10
PCT/EP2011/069849 WO2012062861A1 (en) 2010-11-10 2011-11-10 New adjuvant

Publications (2)

Publication Number Publication Date
MX2013005222A MX2013005222A (es) 2014-04-07
MX345739B true MX345739B (es) 2017-02-14

Family

ID=43795122

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2013005222A MX345739B (es) 2010-11-10 2011-11-10 Nuevo adyuvante.

Country Status (18)

Country Link
US (1) US9187751B2 (es)
EP (1) EP2638062B1 (es)
JP (1) JP5986576B2 (es)
KR (1) KR102010994B1 (es)
CN (1) CN103270048B (es)
AR (1) AR083829A1 (es)
AU (1) AU2011328129B2 (es)
CA (1) CA2817421C (es)
CO (1) CO6731076A2 (es)
EA (1) EA033816B1 (es)
ES (1) ES2676179T3 (es)
HU (1) HUE038386T2 (es)
IL (1) IL226286A0 (es)
MX (1) MX345739B (es)
NZ (1) NZ609952A (es)
PL (1) PL2638062T3 (es)
SG (1) SG190222A1 (es)
WO (1) WO2012062861A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9804158B2 (en) 2013-07-02 2017-10-31 Institut De Recherche Pour Le Développement Peptides and methods for the detection of Leishmaniasis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0893507A1 (en) 1997-07-25 1999-01-27 Institut Gustave Roussy Use of MHC class II ligands (CD4 and LAG-3) as adjuvant for vaccination and of LAG-3 in cancer treatment
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
CA2256124C (en) * 1998-12-23 2015-06-16 C.B.F. Leti S.A. Chimeric gene formed of the dna sequences that encode the antigenic determinants of four proteins of l. infantum, and protein encoded by said gene, and pharmaceutical composition useful for preventing and/or treating leishmaniosis in animals or humans
US6458359B1 (en) * 1998-12-23 2002-10-01 C.B.F. Leti S.A. Chimeric gene formed by the dna sequences that encode the antigenic determinants of four proteins of l. infantum and protein encoded by said gene, and pharmacuetical composition useful for preventing and/or treating leishmaniosis in animals or humans
US6525186B2 (en) 1998-12-23 2003-02-25 C.B.F. Leti S.A. Chimeric gene formed of the DNA sequences that encode the antigenic determinants of four proteins of L. infantum, useful of serologic diagnosis of canine leishmaniosis and protein obtained
FR2826018B1 (fr) * 2001-06-18 2005-01-07 Pasteur Institut Tunis Gene associe a la virulence du parasite leishmania
CA2452909A1 (en) 2001-12-07 2003-06-13 Intercell Ag Immunostimulatory oligodeoxynucleotides
CN1646684B (zh) * 2002-02-21 2010-10-06 免疫医疗疫苗公司 重组副流感病毒表达系统以及包含源自间质肺病毒的异种抗原的疫苗
BRPI0409789B8 (pt) 2003-04-23 2021-05-25 Max Planck Gesellschaft célula bacteriana, seus processos de preparação e seu uso, composição, e processo para a preparação de uma vacina viva
KR100992646B1 (ko) 2003-07-09 2010-11-05 제이에스알 가부시끼가이샤 파장판
RS52507B (en) 2003-11-05 2013-04-30 Laboratorios Leti S.L. APPLICATION OF SPECIFIC HISTONS FOR THE TREATMENT OF PARASITIC DISEASES
CN101977930B (zh) 2008-01-18 2014-12-17 莱蒂实验室私人有限公司 含核糖体蛋白质提取物（RPE)和任选的促Th1佐剂的疫苗
SA110310855B1 (ar) * 2009-11-13 2014-09-16 Laboratories Leti S L Unipersonal استخدام مصدر l3 و/ أو l5 كلقاح أو كوسيلة تشخيصية لمرض طفيلي

Also Published As

Publication number Publication date
EP2638062B1 (en) 2018-04-25
SG190222A1 (en) 2013-06-28
AR083829A1 (es) 2013-03-27
PL2638062T3 (pl) 2018-11-30
JP5986576B2 (ja) 2016-09-06
HUE038386T2 (hu) 2018-10-29
CN103270048A (zh) 2013-08-28
IL226286A0 (en) 2013-07-31
EA033816B1 (ru) 2019-11-28
US20140030293A1 (en) 2014-01-30
WO2012062861A1 (en) 2012-05-18
CN103270048B (zh) 2016-11-23
US9187751B2 (en) 2015-11-17
NZ609952A (en) 2015-05-29
KR20130121863A (ko) 2013-11-06
CA2817421C (en) 2020-04-14
MX2013005222A (es) 2014-04-07
CA2817421A1 (en) 2012-05-18
EA201390670A1 (ru) 2013-10-30
CO6731076A2 (es) 2013-08-15
AU2011328129A1 (en) 2013-05-23
KR102010994B1 (ko) 2019-08-14
AU2011328129B2 (en) 2016-08-11
ES2676179T3 (es) 2018-07-17
EP2638062A1 (en) 2013-09-18
JP2014500719A (ja) 2014-01-16

Similar Documents

Publication Publication Date Title
CA141065S (en) Dual c clip
AU333675S (en) Bottle
CA144407S (en) Lighting
AU333674S (en) Bottle
CA145237S (en) Combined cover and saucer
CA144806S (en) Television
CA144353S (en) Sofa
CA145139S (en) Casing for dispensing device
CA141066S (en) Dual c clip
CA143287S (en) Electric fireplace
CA143991S (en) Dual function wine device
CA144250S (en) Sofa
AU333510S (en) Step
CA145279S (en) Loudspeaker
CA135945S (en) Firelighter
CA143657S (en) Sink
MX345739B (es) Nuevo adyuvante.
GB201106162D0 (en) Combination vaccine
IN2014DN00168A (es)
UA52941U (ru) Применение кардиотрила и его метаболита как кардиопротектора при натрия нитропруссидном стрессе
CA144249S (en) Chair
CA145280S (en) Loudspeaker
CA144805S (en) Television
CA142256S (en) Display device for firearms
CA141261S (en) Measuring device for firearms

Legal Events

Date Code Title Description
FG Grant or registration